secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2024-05-03T23:59:59+00:00
Accession:  0001837607-24-000047
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 4.02
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma restates 2023 financials; non-cash error adds $348M loss; going concern doubt
--------------------------------------------------------------------------------

- Board concludes Q3 2023 and FY 2023 financials unreliable due to IPR&D write-off misclassification.
- Non-cash correction increases reported loss by $348M; cash balances and operating cash flow unaffected.
- Company plans to file restated audited FY 2023 financials and amend Q3 2023 10-Q.
- Expects to disclose additional material weakness and substantial doubt about going concern for 12 months.
- KPMG notified; error has no impact on prior cash or operating cash flow.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760724000047/0001837607-24-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760724000047/aeon-20240501x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-24-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer